Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 66085-59-4 | Product Number: N0896
Nimodipine
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- Isopropyl 2-Methoxyethyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 1G |
£54.00
|
3 | 31 |
|
| 5G |
£186.00
|
Contact Us | ≥40 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | N0896 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__2__6N__2O__7 = 418.45 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 66085-59-4 |
| Reaxys Registry Number | 459792 |
| PubChem Substance ID | 135727105 |
| Merck Index (14) | 6551 |
| MDL Number | MFCD00153848 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 124.0 to 128.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 126 °C |
| Solubility (soluble in) | Methanol |
GHS
Related Laws:
| EC Number | 266-127-0 |
| RTECS# | US7975500 |
Transport Information:
| HS Number | 2933399990 |
Application
ジヒドロピリジン系のL型Ca2+チャンネルアンタゴニスト，ニモジピン
Nimodipine is a dihydropyridine-derivative L-type Ca2+ channel receptor antagonist which relaxes arterial smooth muscle. It may increase the blood pressure lowering effect of concomitantly administered anti-hypertensive agents. Nimodipine is more lipophilic than nifedipine [N0528], and it crosses the blood-brain barrier and reaches brain and cerebrospinal fluid. Therefore, nimodipine has been shown to dilate cerebral arterioles and increase cerebral blood flow in animals. Nimodipine is mainly metabolized by CYP3A4 in the liver, and its plasma concentration can be significantly increased when concomitantly administered with strong CYP3A4 inhibitors. (The product is for research purpose only.)
References
- Pharmacological basis for the use of nimodipine in central nervous system disorders (a review)
- Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease
- Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review
- Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies (a review)
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.